Skip to main content
Equibles

Daniel G. Wildman

Board Member

UroGen Pharma Ltd. (URGN)

Equibles does not estimate personal net worth.

Get an email with a short summary when UroGen Pharma Ltd. publishes a filing, an earnings call transcript or a press release.

Get URGN alerts

About Daniel G. Wildman

Daniel G. Wildman is recorded as Board Member at UroGen Pharma Ltd. (URGN). The newest filing on record that lists Daniel G. Wildman as Board Member at UroGen Pharma Ltd. (URGN) is dated April 30, 2026. UroGen Pharma Ltd. reported in an 8-K filed June 23, 2026 that Daniel G. Wildman was appointed Director, effective June 22, 2026. UroGen Pharma Ltd. reported in an 8-K filed August 27, 2025 that Daniel G. Wildman was appointed director, effective August 26, 2025. UroGen Pharma Ltd. reported in an 8-K filed August 8, 2024 that Daniel G. Wildman was appointed director, effective August 6, 2024. Equibles holds 4 filed executive changes naming Daniel G. Wildman; each is listed under recent activity with its source filing. UroGen Pharma Ltd. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at UroGen Pharma Ltd. includes Elizabeth Barrett (CEO and Board Member), Arie Belldegrun (Chairman and Board Member), Chris Degnan (CFO) and 7 others.

“The shareholders elected the following seven individuals to serve as directors until the Company’s next annual meeting of shareholders and until their successors are elected.”
UroGen Pharma Ltd. Form 8-K, filed June 23, 2026 · Read the filing
“The shareholders elected the following seven individuals to serve as directors until the Company’s next annual meeting of shareholders and until their successors are elected.”
UroGen Pharma Ltd. Form 8-K, filed August 27, 2025 · Read the filing

Affiliation history

Company network

Leadership on record at UroGen Pharma Ltd.

Recent activity